AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05413980 — intervention group
Intervention type: OTHER
Intervention: Moxifloxacin hydrochloride ophthalmic solution
Description: Prospective observational study. There is no treatment allocation. Patients prescribed with 0.5% Moxifloxacin hydrochloride ophthalmic solution during the perioperative period of ophthalmic surgery are eligible to enroll into this study.
Study NCT04851548 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hyaluronic acid
Description: after flap refection, the furcation area will be debrided then add hyaluronic acid 8% and cover it with a collagen membrane
Study NCT05499130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-48574
Description: Subcutaneous infusion
Study NCT05499130 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study NCT05074082 — intervention group
Intervention type: PROCEDURE
Intervention: Flap reconstruction
Description: Formation of a (myo-/fascio-)cutaneous flap for repair of a skin and soft tissue defect
Study NCT04732299 — intervention group
Intervention type: OTHER
Intervention: MRI examination
Description: Magnetic resonance thrombography is used to determine the location of thrombus, quantify the thrombus and determine its stage.
Study NCT05065879 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVAX
Description: 2 doses of Covid-19 vaccine
Study NCT05255432 — intervention group
Intervention type: OTHER
Intervention: nil intervention
Description: Users observation using medical device on manakin, different scenarios per group
Study NCT05003102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hydrochloride - Cycling
Description: Dexmedetomidine Hydrochloride infusion at 0.5 mcg/kg titrated to 0.3 mcg/kg/hr up to a max drip rate of 2 mcg/kg/hr.
Study NCT05003102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Hydrochloride - Cycling
Description: Dexmedetomidine Hydrochloride infusion at 0.5 mcg/kg titrated to 0.3 mcg/kg/hr up to a max drip rate of 2 mcg/kg/hr.
Study NCT05003102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl - PICU Standard
Description: fentanyl infusion at 1 mcg/kg/hr up to a max drip rate of 5 mcg/kg/hr
Study NCT05003102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl - PICU Standard
Description: fentanyl infusion at 1 mcg/kg/hr up to a max drip rate of 5 mcg/kg/hr
Study NCT05003102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hydrochloride - PICU Standard
Description: Dexmedetomidine Hydrochloride infusion at 0.3 mcg/kg titrated to 0.5 mcg/kg/hr up to a max drip rate of 2 mcg/kg/hr
Study NCT05003102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Hydrochloride - PICU Standard
Description: Dexmedetomidine Hydrochloride infusion at 0.3 mcg/kg titrated to 0.5 mcg/kg/hr up to a max drip rate of 2 mcg/kg/hr
Study NCT05065879 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVAX
Description: 2 doses of Covid-19 vaccine
Study NCT05621746 — intervention group
Intervention type: DRUG
Intervention: Esperoct
Description: Participants will be treated with commercially available Esperoct for a total study duration of 24 months according to the local label and local routine clinical practice at the discretion of the physician. The decision to switch to Esperoct will be made prior to and separate from the decision to enrol in the study.
Study NCT04971135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAN711
Description: SAN711 liquid formulation
Study NCT04971135 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT05771337 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: blood sample
Description: blood sample
Study NCT04988802 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prenatal Nutrients Solgar
Description: Patients will take dietary supplement Prenatal Nutrients from Solgar
Study NCT04988802 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules based on starch.
Study NCT04888091 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cotton swab
Description: Removal of the cervical mucus with a cotton swab before embryo transfer.
Study NCT04888091 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cannula
Description: Removal of the cervical mucus with a cannula before embryo transfer.
Study NCT06325566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rexlemestrocel-L + HA mixture
Description: Rexlemestrocel-L will be combined in 1:1 by-volume ratio with HA solution and the resulting mixture will be administered as intradiscal injection.
Study NCT05343416 — intervention group
Intervention type: PROCEDURE
Intervention: Open abdomen procedure
Description: All patients underwent to open abdomen procedure
Study NCT06325566 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: Saline solution injection adjacent to the index disc.
Study NCT05483283 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Empowerment and Navigation
Description: Empowerment and Navigation
Study NCT05483283 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: SOC
Description: SOC
Study NCT06258018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temodal
Description: given orally for 7 consecutive days, followed by 7 days OFF, in a cycle of 28 days
Study NCT06338709 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BariClip® Device Treatment
Description: Device Administration (Implantation)
Study NCT05863507 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Grape powder supplementation
Description: The participants will be willing to consume the grape powder dissolve in water daily for 6 weeks
Study NCT05863507 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participants will be willing to consume the placebo powder, similar to the grape powder, dissolve in water daily for 6 weeks
Study NCT05304416 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fiberoptic Endoscopic Evaluation of Swallowing
Description: This procedure involves inserting a flexible laryngoscope that contains a light source and video camera on the end through the open passage of the nose towards the back of the throat in order to visualize the swallowing mechanism.
Study NCT05304416 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Simultaneous FEES and Videofluoroscopy instrumental swallowing exam
Description: This procedure involves inserting a flexible laryngoscope that contains a light source and video camera on the end through the open passage of the nose towards the back of the throat in order to visualize the swallowing mechanism. The participant will be asked to perform some voicing tasks, once completed, a videofluoroscopic swallowing exam will occur at the same time. This is like a moving x-ray of the participant swallowing foods and liquids (barium).
Study NCT05304416 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Videofluoroscopy instrumental swallowing exam (VFSS)
Description: This is like a moving x-ray of the participant swallowing foods and liquids (barium).
Study NCT05304416 — intervention group
Intervention type: OTHER
Intervention: Voluntary Cough Peak Expiratory Flow (PEF) Testing
Description: Cough PEF will be performed to index a participant's physiologic airway defense capacity and strength. Testing will occur with the participant seated upright at 90 degrees using an analog peak flow meter with a one-way expiratory valve that prevents a participant from breathing air in from the device to reduce contamination.
Study NCT05304416 — intervention group
Intervention type: OTHER
Intervention: Reflex Cough Screen
Description: Participants will be seated upright and administered reflex cough testing via a disposable adult aerosol mask with an attached nebulizer that contains a solution to elicit a cough response.
Study NCT05304416 — intervention group
Intervention type: OTHER
Intervention: Lingual Pressure Testing
Description: Lingual strength will be evaluated using the Iowa Oral Pressure Instrument (IOPI). Participants will be seated upright, and the SLP will place the IOPI air-filled sensing bulb in the midline anterior position on the participant's tongue, posterior to the alveolar ridge.
Study NCT05304416 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Speech Testing
Description: Speech assessment will occur with the participant comfortably seated headset microphone with a lapel windscreen connected to a TASCAM DR40 to allow for high-quality audio recordings. Individuals will be asked to perform two maximal performance speech tasks that include vowel prolongation of /a/, and a Diadochokinetic (DDK) rate task to examine SMR for production of the word buttercup.
Study NCT05557643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Psilocybin is a classic psychedelic of medium duration that is well-tolerated and has a documented safety and efficacy record that makes it uniquely well-suited to the issues that arise in this participant population. Psilocybin has been described as an 'existential medicine' given patient testimonials as to its acute and lasting effects on interpersonal connection, ability to more deeply engage with meaningful activities and relationships, dramatic reductions in fear of death, and a renewed sense of well-being.
Study NCT05557643 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Description: Mindfulness-Based Stress Reduction (MBSR) is a well-established evidence-based mindfulness training program initially developed by Jon Kabat-Zinn that has been shown to reduce symptoms of depression, anxiety, and burnout. The 8-week MBSR curriculum provides training in formal meditation practices including body scan techniques, mindfulness meditation, and yoga. Mindfulness can be understood as the non-judgmental acceptance and investigation of present experience, including body sensations, internal mental states, thoughts, emotions, impulses and memories, in order to reduce suffering or distress and to increase well-being.
Study NCT05557643 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Description: Mindfulness-Based Stress Reduction (MBSR) is a well-established evidence-based mindfulness training program initially developed by Jon Kabat-Zinn that has been shown to reduce symptoms of depression, anxiety, and burnout. The 8-week MBSR curriculum provides training in formal meditation practices including body scan techniques, mindfulness meditation, and yoga. Mindfulness can be understood as the non-judgmental acceptance and investigation of present experience, including body sensations, internal mental states, thoughts, emotions, impulses and memories, in order to reduce suffering or distress and to increase well-being.
Study NCT06023446 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Optical Coherence Tomography
Description: The retina is imaged using infrared light. Images collected in light are compared to those collected in darkness to extract information about function.
Study NCT04505072 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PR-ESSENCE
Description: Manual-based training of mutual problem-solving
Study NCT04505072 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: General support in daily structure and activities that is given to all youth staying at the treatment homes
Study NCT06100263 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized exercise program
Description: guided exercise program for 12 weeks
Study NCT06100263 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Arm
Description: American Cancer Society Physical Activity and the Person with Cancer summary for patients will be provided
Study NCT05051553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fedratinib
Description: Specified dose on specified days
Study NCT05929768 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT05929768 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT04881955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-Ecopipam
Description: \[14C\]-Ecopipam
Study NCT05403411 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Distance education for nursing students on critical thinking
Description: The students in the intervention group were trained with distance education method for the first 4 weeks, and in the following weeks, with theoretical and case presentations. Critical thinking techniques were used during the trainings. A total of 8 weeks of training was given. Training was given for the first 5 weeks without interruption, and for the next three weeks with a two-week break. Critical thinking disposition scale was applied in the pre-test and post-test.
Study NCT05929768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV
Study NCT05929768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT04990622 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flavonoid-rich diet
Description: Inclusion of foods rich in flavonoids.
Study NCT05986877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSA-1201 Subcutaneous injection
Description: Subcutaneous injection
Study NCT05986877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous injection
Study NCT06479304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Oral Tablet
Description: Hydroxychloroquine is taken at the dose of 0.1g / dose, twice a day for 1 year, regardless of food intake.
Study NCT06479304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone tablet
Description: Prednisone is given at the dose of 1mg/kg every morning after meals for 2 weeks ( if platelet count does not recover higher than 30×10\^9/L after 2 weeks, prednisone will be given at the dose for 2 more weeks ), then tapering off.
Study NCT06479304 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone tablet
Description: Prednisone is given at the dose of 1mg/kg every morning after meals for 2 weeks ( if platelet count does not recover higher than 30×10\^9/L after 2 weeks, prednisone will be given at the dose for 2 more weeks ), then tapering off.
Study NCT04782830 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accelerometer
Description: A uniaxial accelerometer-based activity monitor (ActivpalTM) will be worn by participants on one of the thighs during the 7 days of the placebo and treatment periods.
Study NCT04782830 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerometer
Description: A uniaxial accelerometer-based activity monitor (ActivpalTM) will be worn by participants on one of the thighs during the 7 days of the placebo and treatment periods.
Study NCT04782830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo pill
Description: Placebo pill will be taken for 7 days at the same frequency as their regular treatment with either midodrine or atomoxetine.
Study NCT04782830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midodrine or atomoxetine pill
Description: Either midodrine or atomoxetine at their regular dose.
Study NCT05287984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib, Fludarabine, cyclophosphamide and rituximab
Description: Patients aged 65 years or younger who can tolerate FCR.
Study NCT05287984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib, bendamustine, rituximab
Description: For patients older than 65 years or who cannot tolerate FCR regimens.
Study NCT06258018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: given orally in continous
Study NCT06150781 — intervention group
Intervention type: DRUG
Intervention: erenumab-aooe
Description: Dose and treatment duration will be advised by the HCP
Study NCT05485792 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-FAPI PET/CT and 18F-FDG PET/CT
Description: Each subject undergo both 18F-FDG and 68Ga-FAPI PET/CT scans within 1 week
Study NCT06188793 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality-directed BGBT
Description: Enrolled participants will receive up to 3-days of VR-directed BGBT through several modules including distraction games, mindfulness meditation, breathing exercises, and cognitive behavioral therapy based coaching. Participants will complete questionnaires at various time points and be asked to complete a semi-structured interview post-intervention.
Study NCT06580431 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saliva and serum sampling
Description: Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes. Venous puncture was performed after saliva collection and 10 mL of blood samples were collected by qualified staff from each participant. Saliva and serum were then stored at -80 °C until analysis.
Study NCT06580431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saliva and serum sampling
Description: Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes. Venous puncture was performed after saliva collection and 10 mL of blood samples were collected by qualified staff from each participant. Saliva and serum were then stored at -80 °C until analysis.
Study NCT04928105 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Senl-T7
Description: Patients will be treated with CD7 CAR-T cells
Study NCT03266770 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: RELIEF Stent
Description: The RELIEF stent will be placed under cystoscopy. The stent with pusher will be placed over the guidewire and inserted. The pusher will be positioned, the guidewire will be removed, and the pusher will be retracted. The position of the stent will be confirmed by x-ray (C-arm).
Study NCT05929768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV
Study NCT05929768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV
Study NCT05205902 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Low-dose total-skin electron-beam therapy
Description: Low-dose total skin electron beam therapy (12 Gy) will be delivered to the patient in 4 Gy/week, 1 Gy/day over 3 weeks by symmetrical electron beams of 6 MeV energy via a linac accelerator.
Study NCT05205902 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Phototherapy
Description: Phototherapy will be given 3 times a week during 2 months, then twice a week during one month, then once a week during one month, or until disease progression or unacceptable side effect, whatever comes first.~Patients with plaques will receive PUVA therapy and patients with patches only will receive narrow-band UVB therapy.
Study NCT04805255 — intervention group
Intervention type: RADIATION
Intervention: Hypofractionated Stereotactic Radiotherapy
Description: A course of hypofractionated stereotactic radiotherapy (HF-SRT) is delivered within 2 weeks with a cumulative dose of 3000 - 3500 cGy in 5 fractions.
Study NCT06252103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Gluconate 300 MG
Description: iron salt one tab 300 mg contain 35 mg of elemental iron given 2 doses 600 mg per day
Study NCT06252103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ferrous gluconate with lactoferrin
Description: Lactoferrin is a glycoprotein from the transferrin family consist of 691 amino acids,Lactoferrin is a protein found in cow milk and human milk
Study NCT05929768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Given IV
Study NCT05929768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV
Study NCT05929768 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Given IV
Study NCT05929768 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT05929768 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05929768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05929768 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05929768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05929768 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Procedure
Description: Undergo surgery
Study NCT05929768 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Procedure
Description: Undergo surgery
Study NCT06078007 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyMoodCoach
Description: The MyMoodCoach prevention intervention is an evidence-based online intervention based on cognitive-behavioral therapy principles such as behavioral activation, problem solving and challenging negative thoughts.
Study NCT05334485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridostigmine Bromide
Description: Oral 60mg pyridostigmine bromide